Inventors:
David Degraff - Nashville TN, US
Robert Matusik - Nashville TN, US
Peter Clark - Nashville TN, US
Dan Theodorescu - Aurora CO, US
Assignee:
The Regents of the University of Colorado, A body Corporate - Denver CO
VANDERBILT UNIVERSITY - Nashville TN
International Classification:
G01N 33/68
US Classification:
435 792, 436501, 435 71, 435 23
Abstract:
The present invention provides for a proteomic approach to predicting, diagnosing and staging invasive bladder cancer, and for predicting patient survival and therapeutic efficacy. More specifically, the target being analyzed for reduced expression is FOXA1, and optionally including analysis of increased FOXA2 expression.